口服补铁对射血分数降低的心力衰竭合并铁缺乏患者运动能力的影响:IRONOUT HF 随机临床试验
这项2期双盲安慰剂对照随机临床试验纳入225例射血分数降低的心力衰竭(HFrEF,<40%)合并铁缺乏患者,比较口服铁多糖150 mg每日两次与安慰剂共16周。16周时峰值摄氧量变化两组无显著差异(+23 mL/min vs -2 mL/min,差值21 mL/min,95%CI -34至+76,P=0.46),6分钟步行距离、NT-proBNP及KCCQ评分变化亦无显著差异。
要点
- 口服铁多糖150 mg每日两次共16周未改善HFrEF合并铁缺乏患者的峰值摄氧量。
- 6分钟步行距离、NT-proBNP和KCCQ评分变化两组间均无显著差异。
- 作者认为结果不支持在HFrEF患者中使用口服铁补充治疗。
核心结论
- 在HFrEF合并铁缺乏的参与者中,大剂量口服铁未能在16周内改善运动能力。
- 作者认为这些结果不支持在HFrEF患者中使用口服铁补充治疗。
研究设计与样本
- 2期双盲安慰剂对照随机临床试验,纳入HFrEF(<40%)且铁缺乏的患者。
- 铁缺乏定义为血清铁蛋白15至100 ng/mL,或血清铁蛋白101至299 ng/mL且转铁蛋白饱和度低于20%。
- 2014年9月至2015年11月在美国23个中心入组。
- 口服铁多糖组111例,安慰剂组114例,150 mg每日两次共16周。
- 共225例随机,中位年龄63岁,女性36%,203例完成研究。
主要发现
- 口服铁组基线峰值摄氧量中位数1196 mL/min(IQR 887-1448),安慰剂组1167 mL/min(IQR 887-1449)。
- 16周峰值摄氧量变化口服铁组+23 mL/min vs 安慰剂组-2 mL/min,差值21 mL/min(95%CI -34至+76),P=0.46。
- 16周6分钟步行距离变化组间差值-13 m(95%CI -32至6 m),无显著差异。
- 16周NT-proBNP水平变化组间差值159 pg/mL(95%CI -280至599 pg/mL),无显著差异。
- 16周KCCQ评分变化组间差值1(95%CI -2.4至4.4),无显著差异,所有P>.05。
关键数值与推荐
- 主要终点为基线至16周峰值摄氧量变化。
- 次要终点包括6分钟步行距离、血浆NT-proBNP水平和KCCQ评估的健康状态(评分范围0-100,分数越高生活质量越好)。
临床怎么用
- 作者认为结果不支持在HFrEF患者中使用口服铁补充治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Iron deficiency is present in approximately 50% of patients with heart failure with reduced left ventricular ejection fraction (HFrEF) and is an independent predictor of reduced functional capacity and mortality. However, the efficacy of inexpensive readily available oral iron supplementation in heart failure is unknown. OBJECTIVE: To test whether therapy with oral iron improves peak exercise capacity in patients with HFrEF and iron deficiency. DESIGN, SETTING, AND PARTICIPANTS: Phase 2, double-blind, placebo-controlled randomized clinical trial of patients with HFrEF (<40%) and iron deficiency, defined as a serum ferritin level of 15 to 100 ng/mL or a serum ferritin level of 101 to 299 ng/mL with transferrin saturation of less than 20%. Participants were enrolled between September 2014 and November 2015 at 23 US sites. INTERVENTIONS: Oral iron polysaccharide (n = 111) or placebo (n = 114), 150 mg twice daily for 16 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was a change in peak oxygen uptake (V̇o2) from baseline to 16 weeks. Secondary end points were change in 6-minute walk distance, plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels, and health status as assessed by Kansas City Cardiomyopathy Questionnaire (KCCQ, range 0-100, higher scores reflect better quality of life). RESULTS: Among 225 randomized participants (median age, 63 years; 36% women) 203 completed the study. The median baseline peak V̇o2 was 1196 mL/min (interquartile range [IQR], 887-1448 mL/min) in the oral iron group and 1167 mL/min (IQR, 887-1449 mL/min) in the placebo group. The primary end point, change in peak V̇o2 at 16 weeks, did not significantly differ between the oral iron and placebo groups (+23 mL/min vs -2 mL/min; difference, 21 mL/min [95% CI, -34 to +76 mL/min]; P = .46). Similarly, at 16 weeks, there were no significant differences between treatment groups in changes in 6-minute walk distance (-13 m; 95% CI, -32 to 6 m), NT-proBNP levels (159; 95% CI, -280 to 599 pg/mL), or KCCQ score (1; 95% CI, -2.4 to 4.4), all P > .05. CONCLUSIONS AND RELEVANCE: Among participants with HFrEF with iron deficiency, high-dose oral iron did not improve exercise capacity over 16 weeks. These results do not support use of oral iron supplementation in patients with HFrEF. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02188784.
引用
- Lewis GD, Malhotra R, Hernandez AF, et al. Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial. JAMA. 2017. PMID: 28510680. doi:10.1001/jama.2017.5427
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。